Next-gen, effective payloads – from AI-designed small molecules to RNA-based therapeutics and gene therapies – have revolutionized medicine. Yet, the main hurdle remains targeted delivery: avoiding immune reactions (seen with many viral vectors) or undesired organ accumulation (evidenced with LNPs in the liver). Scientists are now harnessing a technology that could overcome these hurdles by using vesicles that cells naturally produce: exosomes.
BioNTech adds clinical weight to its oncology pivot at WCLC 2026
Background, Latest NewsNew data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its mRNA platform. Gotistobart has shown a marked survival benefit in previously treated squamous NSCLC, while the company’s leading bispecific antibody pumitamig continues to generate encouraging signals across tumor types and in combination with an antibody-drug conjugate. The key question now is whether these early signals can translate into registrational success.
Allogenetics adds €3.8M for rejection-resistant donor lungs
Latest NewsHanover-based Allogenetics has raised €3.8 million in a Pre-Series A round to advance ALG-115, an ex vivo gene therapy for donor lungs, through IND-enabling studies and toward a first-in-human trial planned for late 2027 or early 2028.
Simris steps on Heidelberg Pharma’s toes with amanitin pivot
Latest NewsSimris Group is making amanitin-based ADCs the center of its strategy under former Heidelberg Pharma CEO Andreas Pahl — less than two months after hiring the executive who helped build Heidelberg Pharma’s own amanitin platform.
EIB backs Ethris with €30 million for broad-spectrum antiviral mRNA
Latest NewsThe European Investment Bank (EIB) is providing German Ethris with €30 million to advance clinical development of its mRNA-based antiviral candidate ETH47. The Munich-based RNA specialist has been working on the approach for several years. The EIB financing also highlights a persistent challenge in pandemic preparedness: broad-spectrum antivirals may have substantial societal value, but their commercial market is difficult to predict.
Northway opens €61M Vilnius plant built for personalized medicine
Latest NewsCDMO company Northway Biotech has opened a €61 million cell therapy and personalized medicine center in Vilnius that is being qualified for GMP manufacturing, and the company says it expects a manufacturing authorization from Lithuania’s State Medicines Control Agency within six months.
Connecta raises €3.1M for Fragile X syndrome Phase 2
Latest NewsThe Barcelona-based biotech will use the financing to complete a 30-patient Phase 2a study of its lead candidate CTH120, with the first efficacy data expected in mid-2027.
Teitur Trophics reports positive phase 1 data for Parkinson’s peptide
Latest NewsDanish biotech Teitur Trophics completed its phase 1 study and said its experimental Parkinson’s disease treatment TT-P34 was safe and reached the central nervous system, supporting plans to move the peptide into phase 2 testing in 2027.
Leyden Labs reveals RIGImmune acquisition with Phase 1 data
Latest NewsDutch biotech Leyden Labs has reported positive Phase 1 results for intranasal RIG-101 and disclosed that it acquired the drug’s developer, RIGImmune, earlier this year.
Inside exosomes: Nature’s drug carriers
Background, Latest NewsNext-gen, effective payloads – from AI-designed small molecules to RNA-based therapeutics and gene therapies – have revolutionized medicine. Yet, the main hurdle remains targeted delivery: avoiding immune reactions (seen with many viral vectors) or undesired organ accumulation (evidenced with LNPs in the liver). Scientists are now harnessing a technology that could overcome these hurdles by using vesicles that cells naturally produce: exosomes.
Pharvaris oral HAE drug cuts attacks by 83% in Phase 3
Latest NewsSwitzerland-based Pharvaris’ once-daily oral deucrictibant XR reduced hereditary angioedema (HAE) attacks by 83% versus placebo in a pivotal Phase 3 trial, putting the experimental prophylactic into roughly the same efficacy range as several leading injected treatments.